Anti-CRTAM/ CD355 monoclonal antibody

Anti-CRTAM/ CD355 antibody for FACS & in-vivo assay

Target products collectionGo to CRTAM/CRTAM products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0335-Ab-1/ GM-Tg-hg-MP0335-Ab-2Anti-Human CRTAM monoclonal antibodyHuman
GM-Tg-rg-MP0335-Ab-1/ GM-Tg-rg-MP0335-Ab-2Anti-Rat CRTAM monoclonal antibodyRat
GM-Tg-mg-MP0335-Ab-1/ GM-Tg-mg-MP0335-Ab-2Anti-Mouse CRTAM monoclonal antibodyMouse
GM-Tg-cynog-MP0335-Ab-1/ GM-Tg-cynog-MP0335-Ab-2Anti-Cynomolgus/ Rhesus macaque CRTAM monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0335-Ab-1/ GM-Tg-felg-MP0335-Ab-2Anti-Feline CRTAM monoclonal antibodyFeline
GM-Tg-cang-MP0335-Ab-1/ GM-Tg-cang-MP0335-Ab-2Anti-Canine CRTAM monoclonal antibodyCanine
GM-Tg-bovg-MP0335-Ab-1/ GM-Tg-bovg-MP0335-Ab-2Anti-Bovine CRTAM monoclonal antibodyBovine
GM-Tg-equg-MP0335-Ab-1/ GM-Tg-equg-MP0335-Ab-2Anti-Equine CRTAM monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0335-Ab-1/ GM-Tg-hg-MP0335-Ab-2; GM-Tg-rg-MP0335-Ab-1/ GM-Tg-rg-MP0335-Ab-2;
GM-Tg-mg-MP0335-Ab-1/ GM-Tg-mg-MP0335-Ab-2; GM-Tg-cynog-MP0335-Ab-1/ GM-Tg-cynog-MP0335-Ab-2;
GM-Tg-felg-MP0335-Ab-1/ GM-Tg-felg-MP0335-Ab-2; GM-Tg-cang-MP0335-Ab-1/ GM-Tg-cang-MP0335-Ab-2;
GM-Tg-bovg-MP0335-Ab-1/ GM-Tg-bovg-MP0335-Ab-2; GM-Tg-equg-MP0335-Ab-1/ GM-Tg-equg-MP0335-Ab-2
Products NameAnti-CRTAM monoclonal antibody
Formatmab
Target NameCRTAM
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CRTAM benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CRTAM/ CD355 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0335
    Target NameCRTAM
    Gene ID56253,54698,300649,707560,610296,101086672,781864,100071643
    Gene Symbol and SynonymsCD355,CRTAM
    Uniprot AccessionO95727
    Uniprot Entry NameCRTAM_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000109943
    Target ClassificationN/A

    The target: CRTAM, gene name: CRTAM, also named as CD355. The CRTAM gene is upregulated in CD4 (see MIM 186940)-positive and CD8 (see CD8A; MIM 186910)-positive T cells and encodes a type I transmembrane protein with V and C1-like Ig domains (Yeh et al., 2008 [PubMed 18329370]).[supplied by OMIM, Feb 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.